Aurinia Pharmaceuticals Inc. appointed Kevin Tang as CEO and principal executive officer, Ryan Cole as COO, and Michael Hearne as CFO and principal financial officer, effective March 23, 2026, following the departure of prior executives including Peter Greenleaf on March 20, 2026. Craig Johnson was appointed Lead Independent Director effective March 21, 2026.
Key takeaways
Kevin Tang appointed CEO effective 2026-03-23 with no salary, bonuses, or equity
Ryan Cole appointed COO effective 2026-03-23 with $300,000 base salary, 50% target bonus, and option for 150,000 shares
Michael Hearne appointed CFO effective 2026-03-23 with $300,000 base salary, 50% target bonus, and option for 150,000 shares
Peter Greenleaf, prior CEO, ceased as officer on 2026-03-20 and resigned from Board on 2026-03-21, continuing as consultant for 3 months at $600/hour
Matthew Donley (COO), Gregory Keenan (CMO), Joseph Miller (CFO) ceased as officers on 2026-03-20
Craig Johnson elected Lead Independent Director effective 2026-03-21